MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

In July, MSD and Moderna decided to take the combination of the vaccine and Keytruda into a phase 3 trial called INTerpath-001 (formerly V940-001) for skin cancer melanoma, once again as an ...